腹腔镜手术治疗子宫恶性肿瘤52例分析

目的　总结腹腔镜手术治疗子宫恶性肿瘤的临床资料。方法　 1999年 8月至 2 0 0 2年 7月对 37例子宫内膜癌 ,15例子宫颈癌行腹腔镜手术 ,其中广泛全子宫切除加双附件切除术 30例 ,广泛全子宫切除加双附件切除加盆腔淋巴结清扫术 2 2例 ;对子宫内膜癌Ⅰb期G2 、G3 的 14例患者同时行腹主动脉旁淋巴结活检术。结果　 37例子宫内膜癌全部手术成功 ,无一例出现术中并发症 ,平均手术时间 (2 2 0 4 0± 4 7 89)min ,出血量 (96 6 7±33 39)mL ,术前、后诊断符合率 :Ⅰa期 2 0 0 0 % ,Ⅰb期 6 1 90 % ,术后 3年阴道残端复发 1例 ;15例子宫颈癌患者中 ,中转开腹 1例 ,髂外静脉损伤 2例 ,平均手术时间 (316 11± 6 3 2 4 )min ,出血量 (381 6 7± 74 0 9)mL ,平均切除淋巴结 (18 4 3± 1 6 3)粒 ,术后 1年盆腔侧壁复发 1例。腹腔镜手术治疗子宫恶性肿瘤成功率 98 0 8%。结论　腹腔镜手术治疗子宫恶性肿瘤近期效果良好 ,远期效果有待随访。     

子宫内膜癌手术方式的选择与预后

目的 探讨各种手术方式对子宫内膜癌患者预后的影响。方法 收集我院1970～1998年收治的子宫内膜癌患者238例,将所有病例按手术病理分期、病理类型和组织学分级分为低危、中危和高危三组,比较各种手术方式对各组患者预后的影响。结果 低、中危组主要行全子宫加双附件切除术或次广泛子宫切除术,各种术式生存率无显著差异(P>0.05)。高危组Ⅰa+Ⅰb期、Ⅰc期、Ⅱ期行次广泛(或广泛性)子宫切除附加盆腔淋巴结清扫术与单纯行次广泛子宫切除术相比,生存率差异无显著性(P>O.05)。Ⅲ、Ⅳ期主要行次广泛子宫切除术或广泛性子宫切除附加盆腔淋巴结清扫术,这两种术式的生存率差异无显著性(P>0.05)。结论Ⅰa+Ⅰb期腺癌可以单纯行全子宫加双附件切除术或次广泛子宫切除术。Ⅰa+Ⅰb期除腺癌外其他病理类型以及Ⅰc、Ⅱ期可以行广泛性子宫切除术附加盆腔淋巴结清扫术。Ⅲ、Ⅳ期患者预后差,手术方式对预后影响不大。     

不同手术方式对Ⅰ期子宫内膜癌患者的预后分析

目的总结分析不同手术方式对Ⅰ期子宫内膜癌患者的预后,以选择最佳的外科治疗方式。方法回顾性分析上海交通大学医学院附属瑞金医院1995年1月至2008年3月收治的子宫内膜癌患者98例,术前诊断为Ⅰ期。根据手术方式分为两组,A组68例行全子宫双附件切除,B组30例行全子宫双附件切除+盆腔腹主动脉旁淋巴结清扫术,术后随访96~254个月。结果 98例随访率100%。93例最终分期为Ⅰ期的内膜癌病例中,A组5年无瘤生存率88.2%,B组84.0%;术后复发10例(10.8%),其中A组7例,B组3例,两组比较差异无统计学意义(P0.05)。复发者为ⅠA(1/2肌层)G2(肿瘤2 cm)、ⅠB G2、ⅠB G3,及非子宫内膜样腺癌。淋巴结清扫组5例分期上升为ⅢC期,预后不佳。结论对于早期子宫内膜腺癌(ⅠA期),肿瘤细胞分化良好(G1~G2),且无相关高危因素的患者,单纯行全子宫双附件切除术是最佳治疗方案。     

Ⅲ期子宫内膜癌放疗后手术治疗的临床分析

目的:评价全量放疗后全子宫、双附件切除治疗临床Ⅲ期子宫内膜癌的疗效及可行性。方法:回顾分析我院1994～1998年收治的2 6例全量放疗后全子宫、双附件切除治疗的临床Ⅲ期子宫内膜癌患者,通过计算5年生存率、分析手术中及手术后并发症,观察其疗效和并发症。患者采用体外放疗合并腔内放疗,体外照射总量4 0～6 0Gy ,腔内照射总量36～4 2Gy。停放疗后8～16周行全子宫、双附件切除术。结果:2 6例总的5年生存率5 7.9% ,平均手术时间135分钟,平均出血量2 4 2ml,无手术副损伤。局部复发2例(7.6 9% ) ,远处转移4例(15 .38% )。结论:临床Ⅲ期子宫内膜癌全量放疗后行全子宫、双附件切除术,可获得良好的治疗效果,不良反应较少。     

Ⅰ期子宫内膜癌不同术式疗效的研究

目的　对Ⅰ期子宫内膜癌不同术式的疗效及其术后并发症进行比较分析。方法　回顾性分析 1986年 1月至 1997年 12月手术治疗的 2 11例Ⅰ期子宫内膜癌 ,根据术式不同分为两组 ,61例采用全子宫加双侧附件切除术 (组 1) ,150例采用广泛性全子宫切除术 (组 2 )。对两组的疗效及术后并发症进行比较分析。结果　组 1和组 2总的 5年生存率分别为 96 0 %、93 5% ,两组比较 ,差异无显著性 (P >0 0 5) ;复发率分别为 6 6%、10 7% ,两组比较 ,差异无显著性 (P >0 0 5) ;术后并发症分别为 11 5%、2 4 7% ,两组比较 ,差异有显著性 (P <0 0 5)。结论　Ⅰ期子宫内膜癌患者可以采用全子宫加双侧附件切除术     

不同手术方式对Ⅰ期子宫内膜癌患者生存及复发的影响

目的 了解不同手术方式对Ⅰ期子宫内膜癌患者术后生存及复发的影响.方法 回顾性分析1986～1996年行手术治疗的Ⅰ期子宫内膜癌患者110例,根据手术方式不同将其分为3组,行全子宫+双侧附件切除术者为A组(54例);行广泛或次广泛性全子宫切除术者为B组(14例);行全子宫+双侧附件切除(或广泛性全子宫切除或次广泛全子宫切除)+盆腔淋巴结清扫术者为C组(42例),分析3组的生存和复发情况.结果 A、B、C 3组的5年生存率分别为89.5%、90.5%、95.1%,3组间比较,差异无显著性(P>0.05).随诊超过2年的71例中9例复发,复发率为12.7%;9例复发者中7例于3年内复发,其中盆腔局部复发8例,远处转移5例;A、B、C 3组的复发率分别为13.9%、9.1%、12.5%,其中盆腔局部复发率分别为13.9%、9.1%、8.3%,远处转移率分别为2.8%、9.1%、12.5%,分别比较,差异均无显著性(P>0.05).结论 手术方式不是影响Ⅰ期子宫内膜癌患者生存率的主要因素,扩大手术范围或行淋巴结清扫术并不能显著提高患者的生存率.远处转移在术后复发患者中占有相当的比例,辅助治疗时应考虑术后复发的这种特点.     

Ⅰ,Ⅱ期子宫内膜癌治疗方法的评价

目的：评价子宫内膜癌不同治疗方法的效果。方法：对１９８４～１９９２年间收住我院治疗的２０５例Ⅰ期及Ⅱ期子宫内膜癌的临床及病理资料进行回顾性分析。其中临床Ⅰ期１２２例、临床Ⅱ期８３例。按治疗方法不同分为４组：（１）手术组：首选治疗方法为手术者，８１例；（２）术前腔内全量放疗组，６２例。放疗Ｆ点剂量为５０Ｇｙ±１０％，Ａ点剂量为４５Ｇｙ±１０％；（３）术前腔内非全量放疗组，３６例。放疗Ａ点及Ｆ点剂量均＜１／２腔内全量放疗组；（４）单纯放疗组，２６例。４组间病理类型、组织分化程度、中位年龄及手术术式均无统计学差异。结果：４组患者的５年生存率依次为：Ⅰ期：８３．１％、９６．５％、８４．８％、６２．５％；Ⅱ期：８２．０％、９０．９％、５１．４％、６２．７％。术前腔内全量放疗组５年生存率明显为高（Ｐ＜０．０５）。结论：对Ⅰ、Ⅱ期子宫内膜癌，术前行全量腔内放疗是提高疗效的有效方法，术前行部分腔内放疗无明显作用。     

子宫内膜癌患者保留生理功能的治疗

子宫内膜癌是妇科常见恶性肿瘤之一,约75%的患者为早期病例,对于Ⅰ期子宫内膜癌的首选治疗方法为筋膜外全子宫切除、双附件切除及盆腔、腹主动脉旁淋巴结取样和（或）清扫术,术后5年存活率达83%～93%,预后较好.但标准的手术治疗使年轻的子宫内膜癌患者失去了生育机会及卵巢内分泌功能,严重影响患者的生存质量.因此,子宫内膜癌患者保留生理功能的治疗,包括保留年轻子宫内膜癌患者的生育功能或卵巢内分泌功能,以及对手术治疗后的子宫内膜癌患者进行激素替代治疗,成为近年较为关注的问题.     

单纯腹腔细胞学阳性子宫内膜癌Ⅲ a期患者的预后

目的　研究不同子宫内膜癌Ⅲa期患者的预后 ,为临床治疗提供依据。方法　对 1988～ 2 0 0 1年在我院收治的子宫内膜癌Ⅰ期、Ⅲ期患者共 191例进行回顾性分析。患者共分为四组 :第一组为Ⅰ期患者 ,共134例 ;第二组为单纯腹腔细胞学阳性的子宫内膜癌Ⅲa期患者 ,共 2 3例 ;第三组为伴有浆膜浸润或附件转移的子宫内膜癌Ⅲa期患者 ,共 16例 ;第四组为子宫内膜癌Ⅲb期 Ⅲc期患者 ,共 18例。采用Kaplan -Meier法对四组的平均生存时间进行计算 ,并进行比较。结果　①第一组与第二组的平均生存时间差异无显著性 ,P >0 0 5 ;②第二组与第三组的平均生存时间差异有明显统计学意义 ,P <0 0 1;③第三组与第四组的平均生存时间差异无显著性 ,P >0 0 5。结论　尽管腹腔细胞学阳性、浆膜浸润及附件转移均被定为子宫内膜癌Ⅲa期 ,但单纯腹腔细胞学阳性的患者其预后明显好于伴有浆膜层浸润或附件转移者。对她们应采取不同的后续治疗     

FIGOⅠ/Ⅱ期子宫内膜癌病人术后监测

为了解术后监测对Ⅰ/Ⅱ期子宫内膜癌的生存作用,回顾了1978～1987年间354例初次手术治疗未发现转移(FIGO Ⅰ/Ⅱ期)的子宫内膜腺癌临床和病理特性、治疗方式、结果和随访情况。159例(45％)经腹行全子宫+双附件切除和腹膜细胞学检查,195     

Ⅰ期子宫内膜癌128例治疗及预后临床分析

目的了解不同手术方式对Ⅰ期子宫内膜癌患者术后生存及复发的影响.方法回顾性分析Ⅰ期子宫内膜癌128例.根据手术方式不同,将其分为两组,A组;次广泛(或全子宫)+双附件切除术,80例;B组A组术式+盆腔淋巴结清扫术,48例,分析二组生存率及复发情况.结果 A、B两组的5年生存率分别为95.24%,94.87%,两组比较,差异无显著性(P>0.05),随访中,12例复发,复发率11.76%,10例在3年内复发,其中盆腔复发3例,肺转移6例,A、B两组复发率分别为7.94%,17.95%,分别比较,差异均无显著性(P>0.05).结论腹膜后淋巴结切除可明确分期,但不是Ⅰ期子宫内膜癌的治疗手段,扩大手术范围并不能显著提高患者的生存率,远处转移在术后复发中占相当比例,有高危因素时,应考虑辅助治疗.     

Ⅰ期子宫内膜癌腹膜后淋巴结清除术的探讨

目的 探讨Ⅰ期子宫内膜癌的淋巴结转移率及行腹膜后淋巴结清除术的意义。方法 对３８例临床Ⅰ期子宫内膜癌临床、病理及随访资料呃生研究,对照分析经行腹膜后淋巴清除术后,未淋巴转移者２２例,ＦＩＧＯＩ期（Ａ组）,有淋巴结转移者６例,ＦＩＧＯ升级为ⅢＣ期（Ｂ组）及术行腹膜后淋巴清除扔１０例（Ｃ组）结果 经腹膜后淋巴清除术的患者中２１．４％有腹膜后淋巴结转移,因此期别应上升为ⅢＣ期,且腹膜后淋巴结转移与肿瘤细     

盆腔淋巴清扫术对子宫内膜癌预后的影响

目的　探讨子宫内膜癌盆腔淋巴转移的相关因素及盆腔淋巴清扫术对子宫内膜癌预后的影响。方法　选择 1981年 1月至 2 0 0 2年 12月行子宫内膜癌盆腔淋巴清扫术患者 90例 ,淋巴结取样活检术患者 12例 ,分析这 10 2例患者淋巴转移与各临床病理指标的关系。随机选取同期未行淋巴清扫术的 90例患者作为对照与行淋巴清扫术的 90例患者进行比较 ,寿命表法计算两者的生存率。结果　 10 2例患者中 ,低分化、深肌层浸润、宫颈浸润、腹腔冲洗液细胞学检查阳性、附件浸润、远处转移者 ,盆腔淋巴转移的发生率升高 ,分别为 46%、42 %、44%、52 %、75%、10 0 %。盆腔淋巴转移患者的 5年累计生存率 (3 7% )低于无淋巴转移者 (89% ,P <0 0 1)。 90例行盆腔淋巴清扫术患者与对照者的 5年累计生存率分别为 78%和 72 % ,两者比较 ,差异无显著性 (P >0 0 5)。COX逐步回归分析显示 ,盆腔淋巴清扫术不是影响患者预后的独立因素。结论　低分化、深肌层浸润、宫颈浸润、腹腔冲洗液细胞学检查阳性、附件浸润、远处转移是子宫内膜癌盆腔淋巴转移的高危因素 ,有盆腔淋巴转移的患者预后差 ,但盆腔淋巴清扫术并不改善患者预后     

不同手术方式对I期子宫内膜癌患者生存及复发的影响

目的：了解不同手术方式对I期子宫内膜癌患者术后生存及复发的影响。方法：回顾性分析1986－1996年行手术治疗的I期子宫内膜癌患者110例,根据手术方式不同将其分为3组,行全子宫＋双侧附件切除术者为A组（54例）;行广泛或次广泛性全子宫切除术者为B组（14例）;行全子宫＋双侧附件切除（或广泛性全子宫切除或次广泛全子宫切除）＋盆腔淋巴结清扫术者为C组（42例）,分析3组的生存和复发情况。结果：A、B、C3组的5年生存率分别为89．5％、90．5％、95．1％,3组间比较,差异无显著性（P＞0．05）。随诊超过2年的71例中9例复发,复发率为12．7％;9例复发者中7例于3年内复发,其中盆腔局部复发8例,远处转移5例;A、B、C3组的复发率分别为13．9％、9．1％、12．5％,其中盆腔局部复发率分别为13．9％、9．1％、8．3％,远处转移率分别为2．8％、9．1％、12．5％,分别比较,差异均无显著性（P＞0．05）。结论：手术方式不是影响I期子宫内膜癌患者生存率的主要因素,扩大手术范围或行淋巴结清扫术并不能显著提高患者的生存率。远处转移在术后复发患者中占有相当的比例,辅助治疗时应考虑术后复发的这种特点。     

Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy

PURPOSE: The aim of this study was to assess the outcomes of endometrial cancer patients treated with systematic surgery omitting paraarotic lymphadenectomy. PATIENTS AND METHODS: We retrospectively analyzed a consecutive series of 84 endometrioid-type endometrial cancer patients at FIGO Stage I, II or III without grossly metastatic paraaortic lymphadenodes, who underwent surgery at our institute. RESULTS: Sixty-five patients (77%) underwent primary surgery with pelvic lymphadenectomy while the remaining 19 patients underwent surgery without lymphadenectomy due to severe medical complications or age greater than 70 years. The patients with high risk for recurrence were treated mainly by adjuvant irradiation therapy of the whole pelvis. The median follow-up period was 44 months. The 5-year overall survival (OS) rate was 92%, 92% and 65% for FIGO Stage I, II and III, respectively. Recurrence was detected in eight of the 82 optimally operated patients (9.8%). Out of the eight recurrent patients, five patients had a recurrent tumor at extra-pelvic sites (chest or abdomen), two patients had a recurrent tumor only in a paraaortic lymph node, and one patient had a recurrent tumor only in the vagina. Thus, the recurrence rate was relatively low, with 2.4% relapse at the paraarotic lymph nodes, and 5-year OS rate appeared to be favorable. However, all the six recurrent patients who underwent adjuvant radiation therapy had distant recurrence. CONCLUSIONS: These findings indicate that omission of paraarotic lymphadenectomy may be acceptable for endometrial cancer patients without gross metastasis at this site. However, the high rate of distant recurrence after whole pelvic irradiation strongly indicates an urgent need to develop potent systemic adjuvant therapy, potentially by chemotherapy or chemoradiation therapy.     

Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer

OBJECTIVE: The aim of this study was to determine pathologic variables associated with disease-specific survival of node-positive patients with endometrial carcinoma treated with combination of surgery including pelvic and para-aortic lymphadenectomy and adjuvant chemotherapy. METHODS: Survival of 55 node-positive endometrial carcinoma patients prospectively treated with surgery and adjuvant chemotherapy between 1982 and 2002 at Hokkaido University Hospital was compared to various histopathologic variables. All patients underwent primary surgical treatment including pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophosphamide. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis using a forward stepwise selection. RESULTS: Among 303 consecutive endometrial cancer patients treated during the period of this study, 55 patients (18.2%), including 44 without peritoneal metastasis (FIGO stage IIIc) and 11 with peritoneal metastasis (FIGO stage IV), were found to have retroperitoneal lymph node metastasis. Multivariate Cox regression analysis revealed that peritoneal metastasis and lymph-vascular space invasion (LVSI) were independently related to poor survival in node-positive endometrial carcinoma. The estimated 5-year survival rate of stage IIIc patients with or without moderate/prominent LVSI was 50.9% and 93.3%, respectively with statistically significant difference (P=0.0024). The estimated 5-year survival rate of stage IV patients was 20.0%. Prognosis of stage IIIc patients could be stratified into three groups by the number of positive para-aortic node (PAN) with an estimated 5-year survival rate of 86.4% for no positive PAN (n = 23), 60.4% for one positive PAN (n = 13), and 20.0% for > or = 2 positive PAN (n = 8). The difference of survival rate between no or one positive PAN and > or = 2 positive PAN was statistically significant (P = 0.0007 for no positive PAN vs > or = 2 positive PAN, P = 0.0319 for one positive PAN vs > or = 2 positive PAN). Multivariate analysis including number of positive PAN groups showed that LVSI, number of positive PAN groups were independent prognostic factors for survival. Survival of patients with stage IIIc disease could be stratified into three groups by combination of LVSI and number of positive PAN groups with an estimated 5-year survival rate of 93.3% for no or one positive PAN group with nil or minimal LVSI, 62.6% for no or one positive PAN group with intermediate or prominent LVSI, and 20.0% for > or = 2 positive PAN groups irrespective of LVSI (P = 0.0002 for no or one positive PAN group with nil or minimal LVSI vs > or = 2 positive PAN groups, P = 0.0223 for no or one positive PAN group with nil or minimal LVSI vs no or one positive PAN group with intermediate or prominent LVSI, P = 0.0388 for no or one positive PAN group with intermediate or prominent LVSI vs > or = 2 positive PAN groups). CONCLUSIONS: LVSI and number of positive PAN groups were independent prognostic factors for stage IIIc endometrial cancer patients. Postoperative therapy and follow-up modality need to be individualized according to LVSI and the number of positive PAN for stage IIIc patients. New molecular markers to predict the prognosis of endometrial cancer patients preoperatively should be found for individualization of treatment. New chemotherapy regimen including taxane needs to be considered as an adjuvant therapy for patients with node-positive endometrial cancer.     

盆腹腔淋巴取样术在子宫内膜癌手术中的临床意义

目的探讨盆腹腔淋巴取样术在子宫内膜癌的临床意义。方法分析2000年1月-2007年12月上海同济大学附属第一妇婴保健院手术治疗的213例子宫内膜癌患者,其中,86例行盆腹腔淋巴取样术,127例行淋巴结切除术。手术方式根据手术切除淋巴结的情况分为两组。①取样组：淋巴取样术,筋膜外全子宫双附件切除/次广泛子宫切除术＋盆腔/腹主动脉旁淋巴结取样术86例;②切除组：次广泛/广泛子宫切除术＋盆腔淋巴结切除/腹主动脉旁淋巴结切除术127例。结果取样组：切除淋巴结中位数18枚,淋巴结的转移10例。切除组：切除淋巴结中位数32枚,淋巴结转移11例。5年生存率分别为94.2%和94.5%。取样组无病发症发生,淋巴结切除组中有9例,分别是1例术中大出血（〉2000ml）,淋巴囊肿感染6例,淋巴漏2例。结论在子宫内膜癌中淋巴结取样术可准确了解淋巴结的转移情况,适宜手术分期,并不影响生存率,是避免过度手术减少并发症发生的有效方法。     

Anatomical and pathological study of retroperitoneal nodes in endometrial cancer

Benedetti-Panici P, Maneschi F, Cutillo G, D'Andrea G, Manci N, Rabitti C, Scambia G, Mancuso S. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int J Gynecol Cancer 1998; 8 : 322–327.
To assess the patterns of lymphatic spread in endometrial carcinoma, data from 91 endometrial cancer patients (surgical FIGO stage I: 59; II: 12; III–IV: 20) who underwent systematic pelvic and aortic lymphadenectomy were analyzed. The median number of nodes removed was 27 aortic (range 15–57) and 31 pelvic (range 20–68) nodes. Positive nodes were found in 16 patients (18%), seven having pelvic, one aortic, and eight both pelvic and aortic metastasis. The median number of positive nodes was three (range 1–29) aortic and two (range 1–18) pelvic nodes. Isolated pelvic node metastasis was observed in seven patients and aortic metastasis in one patient.
Pre-paracaval, pre-paraortic and intercavoaortic, with superficial obturator, external iliac and common iliac were the node groups most frequently involved. These nodes may be considered primarily invaded by the tumor. The higher prevalence of pelvic with respect to aortic metastasis, and the low risk of isolated aortic spread, suggest that endometrial cancer spreads preferentially to the pelvic area. Multivariate analysis showed that depth of myoinvasion and adnexal metastasis were independent factors predicting the risk of lymphatic spread. The risk of aortic spread was also predicted by the pelvic node status. These data may be useful for tailoring lymphadenectomy.     

Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma

Abstract. Jobsen JJ, Schutter EMJ, Meerwaldt JH, van der Palen J, van der Sijde R, Naudin ten Cate L. Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma.
The aim of this study is to report survival and results of therapy and possible prognostic factors in women with pathologic stage II endometrial carcinoma. Forty-two patients with pathologic stage II endometrial carcinoma were treated at the department of Radiation Oncology of the Medisch Spectrum Twente between 1987 and 1998. All patients received external radiotherapy following standard surgical procedures and no adjuvant systemic therapy was given. From the 42 patients 21 had a pathologic stage IIA and 21 stage IIB. The median follow-up was 62 months. The overall recurrence rate was 21.5% (9/42). Seven patients had distant metastasis, of which three also had locoregional recurrence, vaginal vault and/or pelvic. The presence of myometrial invasion (> ½) and/or lymph-angioinvasion showed a significant relation with distant metastasis ( P = 0.017). Stage IIB showed more recurrences, 33% (7/21). There was a significant different 5-year disease specific survival for stage IIA and IIB, respectively, 95% and 74% ( P = 0.0311). Patients with a differentiation grade 3 and stage IIB showed a significantly poorer ( P = 0.003) 5-year survival of 48.6% ( P = 0.003). Results obtained in the present series of patients are in accordance with the literature. The present treatment policy seems justified, except for patients with pathologic stage IIB and grade 3, in which a more aggressive treatment should be considered.     

化疗对晚期卵巢、输卵管及腹膜浆液性癌淋巴结转移的临床疗效(附70例临床分析)

目的:探讨化疗对晚期卵巢、输卵管及腹膜浆液性癌腹膜后淋巴结转移的临床疗效。方法:将晚期卵巢、输卵管及腹膜浆液性癌70例患者,根据淋巴结切除术与化疗的先后顺序分为2组:A组21例,化疗后行淋巴结切除术。B组49例,淋巴结切除术后化疗。比较2组患者的一般情况、治疗方案及淋巴结转移情况。结果:2组患者的年龄,肿瘤分期分级,治疗前的肿瘤标记物,切除淋巴结的数量等均无显著性差异(P>0.05)。初治时A组患者盆腹腔黏连及转移重于B组;初次手术A组进行满意的肿瘤细胞减灭术的几率明显低于B组(0%vs73.47%,P<0.05)。化疗后A组患者淋巴结转移率低于B组(38.10%vs49.00%,P>0.05),腹主动脉旁淋巴结为肿瘤最常侵犯的淋巴结。A组行TC(泰素/紫杉醇+伯尔定/卡铂)或TP(泰素/紫杉醇+顺铂)方案化疗的患者淋巴转移率低于行CAP(顺铂+阿霉素+环磷酰胺)方案的患者(33.33%vs50%,P=0.045)。结论:化疗对卵巢、输卵管及腹膜浆液性癌淋巴结转移有一定的疗效。初治时不能进行淋巴结切除的患者可考虑先行化疗后再次手术切除淋巴结。